Literature DB >> 27507873

Intellectual Outcome in Molecular Subgroups of Medulloblastoma.

Iska Moxon-Emre1, Michael D Taylor1, Eric Bouffet1, Kristina Hardy1, Cynthia J Campen1, David Malkin1, Cynthia Hawkins1, Normand Laperriere1, Vijay Ramaswamy1, Ute Bartels1, Nadia Scantlebury1, Laura Janzen1, Nicole Law1, Karin S Walsh1, Donald J Mabbott1.   

Abstract

Purpose To evaluate intellectual functioning and the implications of limiting radiation exposure in the four biologically distinct subgroups of medulloblastoma: wingless (WNT), sonic hedgehog (SHH), Group 3, and Group 4. Patients and Methods A total of 121 patients with medulloblastoma (n = 51, Group 4; n = 25, Group 3; n = 28, SHH; and n = 17, WNT), who were treated between 1991 and 2013 at the Hospital for Sick Children (Toronto, Ontario, Canada), Children's National Health System (Washington, DC), or the Lucile Packard Children's Hospital (Palo Alto, CA), had intellectual assessments. First, we compared intellectual trajectories between subgroups. Next, we evaluated the effect of treatment with reduced-dose craniospinal irradiation (CSI) plus a tumor bed boost versus treatments that deliver higher CSI doses and/or larger boost volumes to the brain (all other treatments) within subgroups. Linear mixed modeling was used to determine the stability or change in intelligence scores over time. Results Intellectual outcomes declined comparably in each subgroup except for processing speed; SHH declined less than Group 3 ( P = .04). SHH had the lowest incidence of cerebellar mutism and motor deficits. Treatment with reduced-dose CSI plus a tumor bed boost was associated with preserved intellectual functioning in WNT and Group 4 patients considered together (ie, subgroups containing patients who are candidates for therapy de-escalation), and not in Group 3 or SHH. Across all subgroups, patients in the all other treatments group declined over time (all P < .05). Conclusion SHH patients appear to have the most distinct functional (ie, motor deficits and mutism) outcomes and a unique processing speed trajectory. Only WNT and Group 4 patients seem to benefit from limiting radiation exposure. Our findings highlight the value of conducting subgroup-specific analyses, and can be used to inform novel biologically based treatment protocols for patients with medulloblastoma.

Entities:  

Mesh:

Year:  2016        PMID: 27507873     DOI: 10.1200/JCO.2016.66.9077

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  26 in total

Review 1.  Upfront Therapies and Downstream Effects: Navigating Late Effects in Childhood Cancer Survivors in the Current Era.

Authors:  Rachel Phelan; Hesham Eissa; Kerri Becktell; Neel Bhatt; Matthew Kudek; Brandon Nuechterlein; Lauren Pommert; Ryuma Tanaka; K Scott Baker
Journal:  Curr Oncol Rep       Date:  2019-11-25       Impact factor: 5.075

2.  Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost.

Authors:  Michal Zapotocky; Kiran Beera; Jenny Adamski; Normand Laperierre; Sharon Guger; Laura Janzen; Alvaro Lassaletta; Liana Figueiredo Nobre; Ute Bartels; Uri Tabori; Cynthia Hawkins; Stacey Urbach; Derek S Tsang; Peter B Dirks; Michael D Taylor; Eric Bouffet; Donald J Mabbott; Vijay Ramaswamy
Journal:  Cancer       Date:  2019-02-15       Impact factor: 6.860

3.  Less treatment for Wing less medulloblastoma: germline data re-emphasize this.

Authors:  Anirban Das; Vijay Ramaswamy
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

4.  Cognitive Implications of Ototoxicity in Pediatric Patients With Embryonal Brain Tumors.

Authors:  Traci W Olivier; Johnnie K Bass; Jason M Ashford; Rebecca Beaulieu; Sarah M Scott; Jane E Schreiber; Shawna Palmer; Donald J Mabbott; Michelle A Swain; Melanie Bonner; Robyn Boyle; Mary Lynn Chapeiski; Karen D Evankovich; Carol L Armstrong; Sarah J Knight; Shengjie Wu; Arzu Onar-Thomas; Amar Gajjar; Heather M Conklin
Journal:  J Clin Oncol       Date:  2019-05-02       Impact factor: 44.544

5.  Analysis of surgical and MRI factors associated with cerebellar mutism.

Authors:  Anjali Sergeant; Michelle Masayo Kameda-Smith; Branavan Manoranjan; Brij Karmur; JoAnn Duckworth; Tina Petrelli; Katey Savage; Olufemi Ajani; Blake Yarascavitch; M Constantine Samaan; Katrin Scheinemann; Cheryl Alyman; Saleh Almenawer; Forough Farrokhyar; Adam J Fleming; Sheila Kumari Singh; Nina Stein
Journal:  J Neurooncol       Date:  2017-05-19       Impact factor: 4.130

6.  Survival after chemotherapy and stem cell transplant followed by delayed craniospinal irradiation is comparable to upfront craniospinal irradiation in pediatric embryonal brain tumor patients.

Authors:  David R Raleigh; Bryan Tomlin; Benedict Del Buono; Erika Roddy; Katherine Sear; Lennox Byer; Erin Felton; Anu Banerjee; Joseph Torkildson; David Samuel; Biljana Horn; Steve E Braunstein; Daphne A Haas-Kogan; Sabine Mueller
Journal:  J Neurooncol       Date:  2016-10-24       Impact factor: 4.130

Review 7.  Medulloblastoma: Molecular Classification-Based Personal Therapeutics.

Authors:  Tenley C Archer; Elizabeth L Mahoney; Scott L Pomeroy
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 8.  Long-term Survivors of Childhood Brain Tumors: Impact on General Health and Quality of Life.

Authors:  Priyamvada Gupta; Rakesh Jalali
Journal:  Curr Neurol Neurosci Rep       Date:  2017-11-08       Impact factor: 5.081

Review 9.  Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation.

Authors:  Eduardo Cambruzzi
Journal:  Childs Nerv Syst       Date:  2018-03-26       Impact factor: 1.475

10.  Molecular correlates of cerebellar mutism syndrome in medulloblastoma.

Authors:  Rashad Jabarkheel; Nisreen Amayiri; Derek Yecies; Yuhao Huang; Sebastian Toescu; Liana Nobre; Donald J Mabbott; Sniya V Sudhakar; Prateek Malik; Suzanne Laughlin; Maisa Swaidan; Maysa Al Hussaini; Awni Musharbash; Geeta Chacko; Leni G Mathew; Paul G Fisher; Darren Hargrave; Ute Bartels; Uri Tabori; Stefan M Pfister; Kristian Aquilina; Michael D Taylor; Gerald A Grant; Eric Bouffet; Kshitij Mankad; Kristen W Yeom; Vijay Ramaswamy
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.